Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsTOPICALGeneric

VANIQA

EFLORNITHINE HYDROCHLORIDE

Standard Dose
13.9%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview VANIQA is listed in Drugs@FDA under application 021145 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient EFLORNITHINE HYDROCHLORIDE Form and strength CREAM;TOPICAL - 13.9% Sponsor ABBVIE Submission history Latest submission status date: 2016-02-29 00:00:00.

Structured Monograph

Clinical summary

Approval overview VANIQA is listed in Drugs@FDA under application 021145 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient EFLORNITHINE HYDROCHLORIDE Form and strength CREAM;TOPICAL - 13.9% Sponsor ABBVIE Submission history Latest submission status date: 2016-02-29 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.